Press coverage about Evoke Pharma (NASDAQ:EVOK) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Evoke Pharma earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.8370580237494 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of research firms have issued reports on EVOK. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a research note on Monday, September 18th. Zacks Investment Research downgraded Evoke Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. B. Riley reiterated a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Wednesday, November 15th. FBR & Co reiterated a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Monday, October 30th. Finally, ValuEngine downgraded Evoke Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $9.00.

Shares of Evoke Pharma (NASDAQ:EVOK) traded up $0.01 during midday trading on Friday, hitting $2.65. The stock had a trading volume of 33,082 shares, compared to its average volume of 75,593. Evoke Pharma has a 12-month low of $1.42 and a 12-month high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.13). During the same quarter last year, the firm posted ($0.29) earnings per share. research analysts forecast that Evoke Pharma will post -1 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Evoke Pharma (EVOK) Getting Somewhat Positive News Coverage, Report Finds” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Insider Buying and Selling by Quarter for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc and related companies with's FREE daily email newsletter.